• Lumos has secured 100% reimbursement recognition for FebriDx from all Medicare Administrative Contractors (MAC) at US$41.38 per test
• National Government Services (NGS), the seventh and final MAC, has linked FebriDx with the CMS Clinical Lab Fee Schedule
• Focus now on assisting MACs to develop written policy and ensuring timely and efficient reimbursement claims management

Lumos Diagnostics (ASX: LDX) has announced that it has secured Medicare reimbursement recognition from the seventh and final of the Medicare Administrative Contractors (MAC), National Government Services (NGS). FebriDx, Lumos' rapid point-of-care diagnostic test, has now been linked to the Clinical Lab Fee Schedule from NGS, which is responsible for managing Medicare payments in Illinois, Minnesota, Wisconsin, New England, and New York regions. With the inclusion of NGS, Lumos now has Medicare reimbursement recognition from all seven MACs, representing over 100% of the total US Medicare payment coverage. Medicare comprises approximately 20%-24% of the US payor mix. The next step is to work with each MAC to establish a formal written policy, delivering greater clarity and predictability and enabling more efficient reimbursement processing. Full Medicare coverage also provides meaningful benefits for Medicare Advantage (MA) and Medicaid plans, as these payors frequently reference Centers for Medicare and Medicaid Services (CMS) fee schedules when establishing their own reimbursement frameworks. Lumos' partner, PRO-spectus, will closely engage with these and other private payors to support the integration of this coverage into their internal processes.

The focus now turns to assisting MACs to develop written policy, ensuring timely and efficient reimbursement claims management. Lumos partner, PRO-spectus, will help the MACs and other payors integrate coverage into their policies.